Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men

Abstract

Background:

Reliable biomarkers of androgen activity in humans are lacking. The aim of this study was, therefore, to identify new protein markers of biological androgen activity and test their predictive value in relation to low vs. normal testosterone values and some androgen deficiency linked pathologies.

Methods:

Blood samples from 30 healthy GnRH-antagonist treated males were collected at three time points: a) before GnRH antagonist administration; b) 3 weeks later, just before testosterone undecanoate injection, and c) after additional 2 weeks. Subsequently they were analysed by mass spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins most significantly associated with testosterone fluctuations were further tested in a cohort of 75 hypo- and eugonadal males suffering from infertility. Associations between levels of those markers and cardio-metabolic parameters, bone mineral density as well as androgen receptor CAG repeat lengths, were explored.

Results:

Using ROC analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6) and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/L) vs. normal (> 12 nmol/L) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD levels also showed association with AR CAG-repeat lengths.

Conclusions:

We identified potential new protein biomarkers of testosterone action. Further investigations to elucidate their clinical potential are warranted.

Funding:

The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by the Interreg V EU program.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (60) partner repository with the dataset identifier PXD024448.Supplementary tables (datasets):https://doi.org/10.6084/m9.figshare.14875431Source data of the Figures can be found on:https://doi.org/10.6084/m9.figshare.14875431Supplementary Figure S1 (Figure 2-figure supplement 1):https://doi.org/10.6084/m9.figshare.14876562

The following data sets were generated

Article and author information

Author details

  1. Aleksander Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    For correspondence
    aleksander.giwercman@med.lu.se
    Competing interests
    Aleksander Giwercman, received consulting fees from Besins Healthcare. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5816-0785
  2. K Barbara Sahlin

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  3. Indira Pla Parada

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  4. Krzysztof Pawlowski

    Department of Experimental Design and Bioinformatics, Warsaw University of Life Sciences, Warszawa, Poland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5367-0935
  5. Carl Fehninger

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0922-7749
  6. Yvonne Lundberg Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  7. Irene Leijonhufvud

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  8. Roger Appelqvist

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  9. György Marko-Varga

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  10. Aniel Sanchez

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  11. Johan Malm

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.

Funding

ReproUnion (20201846)

  • Aleksander Giwercman

Swedish Governmental Fund for Clinical Research

  • Aleksander Giwercman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All subjects were enrolled with informed written consent. The two studies from which they were recruited were approved by the Swedish Ethical Review Authority (Approval number: DNR 2014/311, date of approval 8 May 2014; DNR 2011/1, date of approval 11 January 2011).

Copyright

© 2022, Giwercman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 939
    views
  • 163
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Aleksander Giwercman
  2. K Barbara Sahlin
  3. Indira Pla Parada
  4. Krzysztof Pawlowski
  5. Carl Fehninger
  6. Yvonne Lundberg Giwercman
  7. Irene Leijonhufvud
  8. Roger Appelqvist
  9. György Marko-Varga
  10. Aniel Sanchez
  11. Johan Malm
(2022)
Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men
eLife 11:e74638.
https://doi.org/10.7554/eLife.74638

Share this article

https://doi.org/10.7554/eLife.74638

Further reading

    1. Medicine
    Jeong-Oh Shin, Jong-Bin Lee ... Jin-Woo Kim
    Research Article

    This study investigates the effects of two parathyroid hormone (PTH) analogs, rhPTH(1-34) and dimeric R25CPTH(1-34), on bone regeneration and osseointegration in a postmenopausal osteoporosis model using beagle dogs. Twelve osteoporotic female beagles were subjected to implant surgeries and assigned to one of three groups: control, rhPTH(1-34), or dimeric R25CPTH(1-34). Bone regeneration and osseointegration were evaluated after 10 weeks using micro-computed tomographic (micro-CT), histological analyses, and serum biochemical assays. Results showed that the rhPTH(1-34) group demonstrated superior improvements in bone mineral density, trabecular architecture, and osseointegration compared to controls, while the dimeric R25CPTH(1-34) group exhibited similar, though slightly less pronounced, anabolic effects. Histological and TRAP assays indicated both PTH analogs significantly enhanced bone regeneration, especially in artificially created bone defects. The findings suggest that both rhPTH(1-34) and dimeric R25CPTH(1-34) hold potential as therapeutic agents for promoting bone regeneration and improving osseointegration around implants in osteoporotic conditions, with implications for their use in bone-related pathologies and reconstructive surgeries.

    1. Medicine
    2. Neuroscience
    Sophie Leclercq, Hany Ahmed ... Nathalie Delzenne
    Research Article

    Background:

    Alcohol use disorder (AUD) is a global health problem with limited therapeutic options. The biochemical mechanisms that lead to this disorder are not yet fully understood, and in this respect, metabolomics represents a promising approach to decipher metabolic events related to AUD. The plasma metabolome contains a plethora of bioactive molecules that reflects the functional changes in host metabolism but also the impact of the gut microbiome and nutritional habits.

    Methods:

    In this study, we investigated the impact of severe AUD (sAUD), and of a 3-week period of alcohol abstinence, on the blood metabolome (non-targeted LC-MS metabolomics analysis) in 96 sAUD patients hospitalized for alcohol withdrawal.

    Results:

    We found that the plasma levels of different lipids ((lyso)phosphatidylcholines, long-chain fatty acids), short-chain fatty acids (i.e. 3-hydroxyvaleric acid) and bile acids were altered in sAUD patients. In addition, several microbial metabolites, including indole-3-propionic acid, p-cresol sulfate, hippuric acid, pyrocatechol sulfate, and metabolites belonging to xanthine class (paraxanthine, theobromine and theophylline) were sensitive to alcohol exposure and alcohol withdrawal. 3-Hydroxyvaleric acid, caffeine metabolites (theobromine, paraxanthine, and theophylline) and microbial metabolites (hippuric acid and pyrocatechol sulfate) were correlated with anxiety, depression and alcohol craving. Metabolomics analysis in postmortem samples of frontal cortex and cerebrospinal fluid of those consuming a high level of alcohol revealed that those metabolites can be found also in brain tissue.

    Conclusions:

    Our data allow the identification of neuroactive metabolites, from interactions between food components and microbiota, which may represent new targets arising in the management of neuropsychiatric diseases such as sAUD.

    Funding:

    Gut2Behave project was initiated from ERA-NET NEURON network (Joint Transnational Call 2019) and was financed by Academy of Finland, French National Research Agency (ANR-19-NEUR-0003-03) and the Fonds de la Recherche Scientifique (FRS-FNRS; PINT-MULTI R.8013.19, Belgium). Metabolomics analysis of the TSDS samples was supported by grant from the Finnish Foundation for Alcohol Studies.